@drgdiddy When (in due time) $JNJ Janssen announces positive outcomes for JNJ-3989+JNJ-379+Nuc combo study, will be news for $ARWR, bringing new valuation to it’s common stock. Competitors will not matching results so easily. Minimum +5-yr lead on HBV. Great news for CHBV patients, too.